Positron Emission Tomography for Diagnosis of Breast Tumors
- 1 January 1997
- journal article
- review article
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 20 (3) , 190-195
- https://doi.org/10.1159/000218937
Abstract
Positron emission tomography (PET) is a cross-sectional imaging technique that provides functional imaging of the body, e. g., by visualizing metabolic processes. Malignant tissue is characterized by increased glucose metabolism. Currently, the radiolabeled glucose analogue 18F-fluorodeoxyglucose (FDG) is the most common positron-emitting radiopharmaceutical for PET cancer studies. FDG-PET allows the detection of breast cancer with high specificity. The sensitivity of FDG-PET, however, seems to be limited particularly by tumor size. Regional lymph node, bone, liver, and soft-tissue metastases can also be detected. First studies showed the capability of PET to evaluate response to treatment in patients receiving systemic neoadju-vant or palliative therapy. The radiolabeled estrogen analogue 16α-(18F)fluoro-17β-estradiol (FES) allows in vivo assessment of estrogen receptor status in breast cancer tissue.Keywords
This publication has 0 references indexed in Scilit: